Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARTemis-1 Anti-BCMA CAR-T in Relapsed Multiple Myeloma After Allogeneic Transplant
2022-503063-15-00Phase 2Authorised
- Sponsor
- Fundación Pública Andaluza para la Gestión de la Investigación
- Start
- May 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HUVR-CARTemis-1 in multiple myeloma (MM), sponsored by Fundación Pública Andaluza para la Gestión de la Investigación. Primary endpoints: Feasibility of manufacturing and infusion, Maximum tolerated dose and safety of HUVR-CARTemis-1 and 1 more. Planned start May 2024; status: authorised.
02
Drugs
HUVR-CARTemis-1
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2022-503063-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503063-15-00.